Drug Detail


Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

Drug Name LN-145
Trade Name
Synonyms LN145
Drug Descriptions

LN145 comprises autologous tumor infiltrating lymphocytes that are isolated and expanded with IL-2, followed by infusion, potentially resulting in tumor cell death (NCI Drug Dictionary).

CAS Registry Number NA
NCIT ID C135634


  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")


  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Therapy Name Drugs Efficacy Evidence Clinical Trials
Aldesleukin + Cyclophosphamide + Fludarabine + LN-145 + Pembrolizumab Aldesleukin Cyclophosphamide Fludarabine LN-145 Pembrolizumab 0 1
Cyclophosphamide + Fludarabine + Interleukin-12 + LN-145 + Mesna Cyclophosphamide Fludarabine Interleukin-12 LN-145 Mesna 0 1
Durvalumab + LN-145 Durvalumab LN-145 0 1
LN-145 LN-145 0 6
LN-145 + Pembrolizumab LN-145 Pembrolizumab 0 1

Additional content available in CKB BOOST